Healthcare Industry News: benign prostatic hyperplasia
News Release - March 20, 2014
Sophiris Adds Gerald T. Proehl to its Board of DirectorsSAN DIEGO & VANCOUVER, British Columbia--(Healthcare Sales & Marketing Network)--Sophiris Bio Inc. (SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced the appointment of Gerald T. Proehl to its board of directors effective March 19, 2014.
Mr. Proehl most recently served as the president, chief executive officer and director of Santarus, Inc. until its acquisition by Salix Pharmaceuticals, Inc. in January 2014. Mr. Proehl had served in these capacities since January 2002. From March 2000 through December 2001, Mr. Proehl was the president and chief operating officer of Santarus. From April 1999 to March 2000, Mr. Proehl served as vice president, marketing and business development of Santarus. Prior to joining Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, for 14 years. At Hoechst Marion Roussel, he served in various capacities in multiple therapeutic areas and was responsible for the marketing of gastrointestinal products Carafate and Pentasa, among products in several other therapeutic areas. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.
“Gerry brings a wealth of relevant experience to our board of directors especially in the areas of commercialization, business development and strategic planning,” said Randall E. Woods, president and CEO of Sophiris. “These areas are especially important for a company at our stage of development as we continue to execute on our long term strategic plan.”
Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris initiated its first Phase 3 clinical trial of PRX302 in October 2013. For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial enrollment and results, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Sophiris Bio
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.